Design, synthesis and in vivo activity of 9-(S)-dihydroerythromycin derivatives as potent anti-inflammatory agents

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 22, 2006, Pages 5801-5804

  Mereu, A ^a   Moriggi, E ^a   Napoletano, M ^a   Regazzoni, C ^a   Manfredini, S ^b   Mercurio, T P ^b   Pellacini, F ^a  

^a Zambon Group   (Switzerland)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

amide; Amine; Anti inflammatory; CD1 mice; Cladinose; Desosamine; Erythromycin; Erythronoid; Macrolide; PMA induced ear edema

Indexed keywords

ANTIINFLAMMATORY AGENT; ERYTHROMYCIN DERIVATIVE; MACROLIDE; SUGAR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; DRUG ACTIVITY; DRUG DESIGN; DRUG SYNTHESIS; EDEMA; IN VIVO STUDY; MOUSE; NONHUMAN;

AMINO SUGARS; ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; EDEMA; ERYTHROMYCIN; MICE;

EID: 33749436415     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.08.076     Document Type: Article

References (21)

1. Retsema J., and Fu W. Int. J. Antimicrob. Agents 18 (2002) S3
2. Tamaoki J., Kadota J., and Takizawa H. Am. J. Med. 117 (2004) 5S
3. Swords W.E., and Rubin B.K. Neth. J. Med. 61 (2003) 242
4. Tamaoki. J. Chest 125 (2004) 41S
5. Theron A.J., Feldman C., and Anderson R. J. Antimicrob. Chemother. 46 (2000) 269
6. Napoletano, M; Moriggi, E; Mereu, A; Ornaghi, F; Morazzoni, G; Longoni, R; Riva, C; Pacchetti, L; Pellacini, F. Int. Patent WO 2004/013153.
7. Tanikawa T., Asaka T., Kashimura M., Misawa Y., Suzuki K., Sato M., Kameo K., Morimoto S., and Nishida A. J. Med. Chem. 44 (2001) 4027
8. Radolph J.T., Sauer D.R., Haviv F., Nilius A.M., and Greer J. Bioorg. Med. Chem. Lett. 14 (2004) 1599
9. Lartey P.A., Faghih R., Pagano T., Nellans H.N., Petersen A., and Plattner J.J. J. Antibiot. 48 (1995) 730
10. Chen W.-M., Wong H.N.C., Chu D.T.W., and Lin X. Tetrahedron 59 (2003) 7033
11. Radolph J.T., Waid P., Nichols C., Sauer D.R., Haviv F., Diaz G., Bammert G., Besecke L.M., Segreti J.A., Mohning K.M., Bush E.N., Wegner C.D., and Greer J. J. Med. Chem. 47 (2004) 1085
12. Lartey P.A., Nellans H.N., Faghih R., Petersen A., Edwards C.M., Freiberg L., Quigley S., Marsh K., Klein L.L., and Plattner J.J. J. Med. Chem. 38 (1995) 1793
13. Smissman E.E., and Makriyannis A. J. Org. Chem. 33 (1973) 1652
14. Denis A., and Renou C. Tetrahedron Lett. 43 (2002) 4171
15. Greene T.W., and Wuts P.G.M. Protective Groups in Organic Synthesis (1999), John Wiley and Sons, New York pp. 526-528
16. Kocienski P.J. Protecting Groups (1994), Thieme, Stuttgart pp. 199-202
17. 3 in aqueous methanol media at 60 °C. Ku Y.-Y., Riley D., Patel H., Yang C., and Liu J.-H. Bioorg. Med. Chem. Lett. 7 (1997) 1203
18. The cytotoxicity of macrolide compounds was evaluated in vitro in a human hepatocellular carcinoma cell line (Hep G2) by measuring the cellular metabolic function.
19. The ability of macrolide compounds to modulate the oxidase activity of phagocytic cells (reactive oxygen species production) was tested in vitro in human whole blood.
20. 2 inhalation. The edema was evaluated by weighting a constant portion of the treated ear pinna, in comparison with the untreated controlateral one
21. The 'in vitro' antibacterial effect of macrolides was evaluated on different bacterial strains: Streptococcus pneumoniae (ATCC 49619), Staphylococcus aureus (ATCC 29213 or ATCC 6538), Enterococcus faecalis (ATCC 29212), and Streptococcus pyogenes (ATCC 19615).